Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.61 |
| ▸ | NPY1R | P25929 | 8/20 | 0.61 |
| ▸ | NPY2R | P49146 | 6/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.61 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184229 | 0.91 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5RNTSR2 | |
| SCHEMBL30799753 | 0.85 | NPY4R (0.66) | NPY4RNPY1RNPY2RNPY5RNTSR2 | |
| SCHEMBL16468898 | 0.85 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNTSR2 | |
| SCHEMBL30471386 | 0.84 | NPY4R (0.76) | NPY4RNPY1RNPY2RNPY5RNTSR2 | |
| SCHEMBL31589813 | 0.82 | NPY4R (0.73) | NPY4RNPY1RNPY2RNPY5RNTSR2 | |
| SCHEMBL30179204 | 0.82 | NPY4R (0.73) | NPY4RNPY1RNPY2RNPY5RNTSR2 | |
| SCHEMBL29760947 | 0.82 | NPY4R (0.68) | NPY4RNPY1RNPY2RNPY5RNTSR2 | |
| SCHEMBL29608100 | 0.82 | NPY4R (0.67) | NPY4RNPY1RNPY2RNPY5RNTSR2 | |
| SCHEMBL31114986 | 0.81 | NPY4R (0.69) | NPY4RNPY1RNPY2RNPY5RNTSR2 | |
| SCHEMBL2193857 | 0.81 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5ROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | NPY4R 2480/4885NPY1R 3329/4885NPY2R 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.